These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1533 related items for PubMed ID: 9099457
1. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E. Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [Abstract] [Full Text] [Related]
2. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737 [Abstract] [Full Text] [Related]
3. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Cancer; 2002 Dec 01; 95(11):2302-7. PubMed ID: 12436435 [Abstract] [Full Text] [Related]
15. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA, Katcher J, Levin HS, Klein EA. Int J Radiat Oncol Biol Phys; 1997 Mar 15; 37(5):1043-52. PubMed ID: 9169811 [Abstract] [Full Text] [Related]
16. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332 [Abstract] [Full Text] [Related]
17. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR, Presti JC, Brooks JD, Gill H, Spiotto MT. Int J Radiat Oncol Biol Phys; 2008 Apr 01; 70(5):1472-7. PubMed ID: 17935902 [Abstract] [Full Text] [Related]
18. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M. Can J Urol; 2009 Oct 01; 16(5):4813-9. PubMed ID: 19796456 [Abstract] [Full Text] [Related]
20. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W. Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1009-16. PubMed ID: 18963539 [Abstract] [Full Text] [Related] Page: [Next] [New Search]